Table 1.
Eligible studies for the systematic review and their study characteristics.
| Author | Year | Blood-Based Biomarker | Sample Size | Study Design | Survival Outcomes |
|---|---|---|---|---|---|
| Chang et al. [27] | 2004 | CA 125 | n = 287 | retrospective single-center | RFS, OS |
| Kouba et al. [28] | 2009 | CA 125 | n = 92 | prospective single-center | recurrence |
| Hazzaa et al. [29] | 2010 | clusterin | n = 26 | prospective single-center | RFS, OS |
| Rink et al. [30] | 2012 | HER2 expression of circulating tumor cells | n = 100 | prospective single-center | OS, CSS, RFS |
| Ahmadi et al. [31] | 2014 | CA 19-9, CA 125, CEA | n = 186 | prospective single-center | OS, RFS |
| Hermanns et al. [32] | 2014 | NLR | n = 424 | retrospective single-center | OS, CSS, RFS |
| Viers et al. [33] | 2014 | NLR | n = 899 | retrospective single-center | OS, CSS, RFS |
| Djaladat et al. [34] | 2014 | albumin level, ASA score | n = 1471 | retrospective single-center | RFS, OS |
| Morizawa et al. [22] | 2016 | NLR | n = 110 | retrospective single-center | OS, CSS, RFS |
| Bhindi et al. [20] | 2016 | hemoglobin, individual cell counts, NLR, MLR, LMR, PLR | n = 418 | retrospective single-center | OS, CSS, RFS |
| Liu et al. [35] | 2016 | albumin/globulin ratio | n = 296 | retrospective multicenter | RFS, CSS |
| Tan et al. [36] | 2017 | NLR | n = 84 | retrospective single-center | OS, CSS, RFS |
| D’Andrea et al. [21] | 2017 | LMR, NLR | n = 4198 | retrospective multicenter | OS, CSS, RFS |
| Christensen et al. [37] | 2019 | circulating tumor DNA | n = 68 | prospective single-center | RFS, OS |
| Yuk et al. [38] | 2019 | De Ritis ratio | n = 771 | retrospective single-center | OS, CSS, RFS |
| Ninomiya et al. [39] | 2020 | NLR, MLR, LPR, De Ritis ratio, PNI | n = 107 | retrospective single-center | OS, RFS |
| Fallah et al. [40] | 2020 | Myeloid-derived suppressor cells | n = 109 | retrospective single-center | OS, RFS |
| Su et al. [41] | 2020 | lactate dehydrogenase | n = 263 | retrospective single-center | OS, CSS, DFS |
| Dohn et al. [42] | 2021 | uPA | n = 107 | prospective single-center | OS, CSS, RFS |
| Schuettfort et al. [43] | 2021 | albumin-globulin ratio | n = 4335 | retrospective multicenter | OS, CSS, RFS |
| Li et al. [44] | 2021 | albumin-to-alkaline phosphatase ratio | n = 199 | retrospective single-center | OS, CSS, RFS |
| Mari et al. [45] | 2021 | inflammatory biomarkers | n = 255 | retrospective single-center | recurrence, CSM, OM |
| Schuettfort et al. [46] | 2021 | uPA, SuPAR, PAI-one | n = 1036 | retrospective multicenter | RFS, CSS |
| Schuettfort et al. [47] | 2022 | panel of SIR markers | n = 4199 | retrospective multicenter | CSS, RFS |
| Grossmann et al. [48] | 2022 | systemic immune-inflammation index | n = 4335 | retrospective multicenter | OS, CSS, RFS |
| Laukhtina et al. [49] | 2022 | endoglin | n = 1036 | retrospective multicenter | OS, CSS, RFS |
| Sari Motlagh et al. [50] | 2022 | IGF-I, IGFBP-2, IGFBP-3 | n = 1036 | retrospective multicenter | OS, CSS, RFS |
| Mori et al. [51] | 2022 | VCAM-1 | n = 1036 | retrospective multicenter | OS, CSS, RFS |
| Lei et al. [52] | 2022 | NLR, PLR, LMR | n = 186 | retrospective single-center | RFS |
| Schuettfort et al. [53] | 2022 | Interleukin-6 and its soluble receptor | n = 1036 | retrospective multicenter | OS, CSS, RFS |
| Urabe et al. [54] | 2022 | Serum microRNA | n = 81 | retrospective single-center | OS, PFS |
| Katayama et al. [55] | 2022 | hepatocyte growth factor | n = 565 | retrospective multicenter | OS, CSS, RFS |
| Mori et al. [51] | 2022 | VEGF plasma levels | n = 1036 | retrospective multicenter | OS, CSS, RFS |
uPA = urokinase-type plasminogen activator, CA = carbohydrate antigen, CEA = carcinoembryonic antigen, HER = human epidermal growth factor receptor, SIR = systemic inflammatory response, LMR = lymphocyte-to-monocyte ratio, NLR = neutrophil-to-lymphocyte ratio, IGF = insulin-like growth factor, IGFBP = insulin-like growth factor-I binding protein, suPAR = urokinase-type plasminogen activator soluble receptor, PAI = urokinase-type plasminogen inhibitor, VCAM = vascular cell adhesion molecule, MLR = monocyte-to-lymphocyte ratio, LPR = lymphocyte-to-platelet ratio, PNI = prognostic nutritional index, PLR = platelet-to-lymphocyte ratio, ASA = American Society of Anesthesiologists, OS = overall survival, CSS = cancer-specific survival, RFS = recurrence-free survival, CSM = cancer-specific mortality, OM = overall mortality, VEGF = vascular endothelial growth factor, PFS = progression-free survival, DFS = disease-free survival.